secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2023-07-11T23:59:59+00:00
Accession:  0001493152-23-024176
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix submits IND for PUR3100 Phase 2 trial in acute migraine
-----------------------------------------------------------------

- IND submitted to FDA for PUR3100, an inhaled dry powder DHE formulation for acute migraine.
- Phase 1 data showed PK similar to IV DHE with fewer side effects.
- Phase 2 protocol investigates safety and preliminary efficacy in migraine patients.
- Approximately 40 million U.S. patients with acute migraine need additional options.
- PUR3100 uses proprietary iSPERSE dry powder delivery technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223024176/0001493152-23-024176-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315223024176/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-024176

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer